Johnson & Johnson (JNJ)vsSmith & Nephew SNATS Inc (SNN)
JNJ
Johnson & Johnson
$266.38
+0.30%
HEALTHCARE · Cap: $640.02B
SNN
Smith & Nephew SNATS Inc
$27.50
-0.43%
HEALTHCARE · Cap: $12.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 1454% more annual revenue ($97.93B vs $6.30B). JNJ leads profitability with a 21.5% profit margin vs 10.1%. SNN appears more attractively valued with a PEG of 1.10. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
SNN
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-88.9%
Fair Value
$140.57
Current Price
$266.38
$125.81 premium
Intrinsic value data unavailable for SNN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Every $100 of equity generates 22 in profit
Areas to Watch
Premium valuation, high expectations priced in
Expensive relative to growth rate
Earnings declined 0.9%
Trading at 11.3x book value
4.6% revenue growth
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bull Case : SNN
The strongest argument for SNN centers on Return on Equity. PEG of 1.10 suggests the stock is reasonably priced for its growth.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : SNN
The primary concerns for SNN are Price/Book, Revenue Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while SNN is a value play — different risk/reward profiles.
SNN carries more volatility with a beta of 0.68 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 55/100), backed by strong 21.5% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Smith & Nephew SNATS Inc
HEALTHCARE · MEDICAL DEVICES · USA
Smith & Nephew plc develops, manufactures, markets and sells medical devices worldwide. The company is headquartered in Watford, the United Kingdom.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?